Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 5, May, p. 679–682

doi: 10.17219/acem/94164

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Antiviral immunity in chronic lymphocytic leukemia measured by anti-rubella antibody

Jadwiga Nowicka1,A,B,C,D,E, Piotr Milejski2,A,C,E,F, Iwona Urbanowicz3,B,C,D, Przemysław Niewiński2,C,D,F

1 Department of Clinical Chemistry, Department of Hematology, Wroclaw Medical University, Poland

2 Department of Clinical Pharmacology, Wroclaw Medical University, Poland

3 Department of Hematology, Wroclaw Medical University, Poland

Abstract

Background. Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia in Caucasian populations, is characterized by a decrease in anti-infective immunity. Clinical evidence of antiviral immunity decrease is the reactivation of herpes virus in the form of skin lesions. In Europe, rubella infection is common and creates lifelong persistence of IgG antibodies.
Objectives. The aim of our study was to determine whether hemagglutination inhibition (HAI) rubella test can be used to determine antiviral immunity in CLL patients.
Material and Methods. The titers of the HAI test against rubella were examined in a group of 26 healthy subjects, 7 subjects with herpes labialis infection and 56 patients with CLL, among which 9 patients were co-infected with herpes virus.
Results. Statistical tests have shown differences between groups and a significant decrease of the titers of the test in patients with CLL, compared with healthy persons and the herpes group compared with other persons.
Conclusion. Our results indicate a significant decrease of antiviral immunity in patients with CLL and persons with herpes-type skin lesions. Simultaneously, relying on our previous studies, we also suggest that the result of this test may be an important indicator of antiviral immunity in patients with CLL.

Key words

chronic lymphocytic leukemia, herpes, antiviral immunity, rubella HAI test

References (16)

  1. Yokota S, Okabayashi T, Furii N. The battle between virus and host: Modulation of toll-like receptor signaling pathways by virus infection. Mediators of Inflamation. Vol. 2010, article ID 184328. doi:1155/2010/184328
  2. Arista S, Pistoja D, Titone L, Ammaturia P. Comparison of serological methods for the detection of IgG and IgM antibodies to rubella viruses. Microbiologica. 1987;10:151–160.
  3. National Committee for Clinical Laboratory Standards (NCCLS). Evaluation and Performance Criteria for Multiple Component Test Product Intended for the Detection and Quantification of Rubella IgG Antibody: Tentative Guideline, NCCLS Document 1/LA6-T. Villanova: NCCLS, 1992.
  4. Goodson JL, Masresha B, Dosseh A, et al. Rubella epidemiology in Africa in the prevaccine era, 2002–2009. J Infect Dis. 2011;204(Suppl 1):S215–225.
  5. Siennicka J, Stefanoff P, Rogalska J, Trzcińska A. Etiology of measles suspect cases reported in 2006–2007 in Poland. Przegl Epidemiol. 2011;65(1):39–44.
  6. Smith G. Herpes virus transport to the nervous system and back again. Annu Rev Microbiol. 2012;66:153–176.
  7. Agnew KL, Ruchlemer R, Catovsky D, Matutes E, Bubker CB. Cutaneous findings in chronic lymphocytic leukemia. Br J Dermatol. 2004;150(6):1129–1135.
  8. Smith E, Hallman JR, Pardasoni A, McMichael A. Multiple herpetic whitlow lesions in a patient with chronic lymphocytic leukemia. Am J Hematol. 2002;69(4):285–288.
  9. Romer A, Greiner A, Euk A, Hartschuh W. Herpes simplex vegetans: Atypical genital herpes infection with prominent plasma cell infiltration in B-cell chronic lymphocytic leukemia. J Dtsch Dermatol Ges. 2009;6(10):865–867.
  10. Milejski P, Nowicka J, Masiak M, Orzechowska-Juzwenko K, Kotlarek-Haus S. Rubenosticon in haematological and lymphoreticular disorders [in Polish]. Pol Tyg Lek. 1984;39(24):815–818.
  11. Tsiodras S, Samsons G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc. 2000;75(10):1039–1054.
  12. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008:450–456.
  13. Ravandi F, O’Brien S. Infections associated with purine analogs and monoclonal antibodies. Blood Rev. 2005;19(5):253–273.
  14. Morrison VA. Infectious complications of chronic lymphocytic leukemia: Pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145–153.
  15. Borthakur G, Lin E, Faderl S, et al. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer. 2010;110(11):2478–2483.
  16. Nowicka J, Milejski P, Orzechowska-Juzwenko K, Unolt J. Rubenosticon test as a marker of depressed humoral immunity in myeloma multiplex. Acta Heamatol Pol. 1997;28:163–168.